Navigation Links
XTENT Announces Fourth Quarter 2008 Financial Results and Business Progress
Date:2/19/2009

expenditures incurred in the first quarter of 2009.

Piper Jaffray & Co. has been engaged to help the company pursue strategic alternatives intended to maximize shareholder value which could include a sale of one or more of our non-core assets, such as our peripheral stent product or our bioabsorbable stent technology, a sale of all our assets or a merger.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.

Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's expectations with respect to the timing and amount of any savings that may result from the company's cost reduction initiatives, the timing and amount of any expenses that may be incurred as a result of the company's headcount reduction and the potential for becoming a party to a strategic transaction. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from
'/>"/>

SOURCE XTENT, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. XTENT Announces Third Quarter 2007 Financial Results
2. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
3. XTENT Announces 2007 Financial Results Conference Call
4. New study shows extent of harmful human influences on global ecosystems
5. XTENT Announces 2007 Financial Results
6. XTENT to Present at Cowen and Companys 28th Annual Health Care Conference
7. XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention
8. XTENT Appoints Christopher M. Smith and Arthur T. Taylor to Board of Directors
9. XTENT Announces Second Quarter 2008 Financial Results and Business Progress
10. XTENT Announces Third Quarter 2008 Financial Results
11. APIC Covers Up Extent and Causes of Deadly C. diff
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... After more than ... Food and Drug Administration, GlobalSun (TM) — sunscreen specifically formulated for the unique skin ... rating of 35, hits the market just in time to help protect the skin ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... drug response profiling test to help oncologists provide personalized cancer treatment, will ... CorrectChemo® assay provides the oncologist with valuable insight on how a specific ...
(Date:6/30/2015)... Vancouver, BC (PRWEB) , ... June 30, 2015 ... ... authority in medical device market research, has launched a new reimbursement insurance policy ... and healthcare professionals to receive US insurance policy and rate updates in real-time ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... The company provides high quality record management services for patient records. Medical imaging ... normally required by physicians and clinics. , With the increase in the ...
(Date:6/30/2015)... ... June 30, 2015 , ... The Citizens Commission ... Davis (D-IL) for writing to the Department of Health and Human Services (HHS), ... healthcare system, Universal Health Services (UHS).[1] CCHR is expanding its seven-year review of ...
Breaking Medicine News(10 mins):Health News:GlobalSun – The First Sunscreen Developed for All People of Color – Hits The Market 2Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 2Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 3Health News:iData Research Introduces New Medical Insurance Reimbursement Policy & Rate Tracker Subscription Service 2Health News:Micro Com Systems Ltd Now Specializes in Medical Imaging 2Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 2Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 3Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 4Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 5
... blood fats called triglycerides to an increased risk of ... attention to triglyceride levels.// More effective screening and detection ... stroke risk factor could further reduce the stroke burdens. ... blood fats can also prevent strokes. The precise relationship ...
... to hold the American Red Cross in contempt of court ... is acting today to ensure that the Red Cross takes ... of the nation's blood supply, which is essential to the ... the Red Cross in a 1993 consent decree to make ...
... treating childhood brain tumours, aimed at reducing the risk of ... around the US. Researchers will enrol 50 children suffering from ... who will be treated with lower radiation and increased chemotherapy ... US, about 500 children are diagnosed with this curable condition ...
... born during the night have a greater risk of infant ... There is also a greater chance of death for those ... staff shift changes. ,The research found the hours between ... observations confirm previous reports that infants born at night have ...
... children who are overweight will grow up to be overweight ... mass index in childhood is very often reflected in body ... and fattest as adults tended to have the highest adult ... health records of 1,142 children. Two-thirds of the group// were ...
... Kansas State University have published the first evidence that ... in the egg, the lecithin.,The research was done ... Noh. A peer-reviewed research paper by the three researchers, ... rats,” as in the Journal of Nutrition.// ,Many ...
Cached Medicine News:Health News:Lecithin lowers cholesterol absorption in body 2
(Date:6/30/2015)... -- Pulse Light Clinic in London,s ... as part of their ongoing research into the condition. They ... their Rosacea. The survey participants were aged between 20 and ... women. The results revealed some rather surprising statistics: ... attempt to visit their GP for Rosacea treatment. ...
(Date:6/30/2015)... 30, 2015 First Choice Wellness Care recently ... Duality and is the only clinic in the greater ... removal treatments. The practice has recently expanded their services ... to showcase their focus in the procedure. They upgraded ... faster ink clearance, and superior service. "We,ve ...
(Date:6/30/2015)... 2015  Avanir Pharmaceuticals, Inc. today announced top-line ... treatment with NUEDEXTA ® was associated with ... affect (PBA) in patients with traumatic brain injury ... characterized by sudden and uncontrollable outbursts of laughing ... brain injury. PRISM II is a phase IV ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7
... 2011 Fuisz ( www.fuisz.com ) today announced the ... Permitting Stage Door Access to On-Line Vendor Information"). ... "This patent covers a system that allows a customer ... a product supplier database through the on-line vendor,s system ...
... 15, 2011 Cardium Therapeutics (NYSE Amex: ... from the Russian Ministry of Health and Social Development ... Company,s Generx™ (alferminogene tadenovec, Ad5FGF-4) biologic product candidate.  Generx ... for the potential treatment of myocardial ischemia due to ...
Cached Medicine Technology:Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 2Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 3Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 4Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 5Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 6Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 7
Shandon Microscope Slide Cabinet with Drawers...
... data from multiple sources is not ... ResultNet/Plus software allows you to concentrate ... communications network., ,ResultNet/Plus eliminates the complexity ... largescale or multi-site laboratories to host ...
The flexible EXXCEL ePTFE Vascular Access Graft material is designed to offer textile-like handling characteristics-cuts neatly for a clean edge, retains fully open lumen shape, and sutures smoothly....
ACE Control Serum provides the laboratory with vital information on the performance of the ACE chemistry assay....
Medicine Products: